In a research note issued to investors, Vernon Bernardino at MLV & Co Reiterated their Hold rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT). The analyst placed a $273.00 price target on the stock which indicates a 7.11% downside to the last closing price. In the year following Bernardino’s ratings, the stocks covered yield an average return of -8.40% according to TipRanks.com. In the past year 17 out of 45 recommendations or 38% were successful.
Wall Street sell-side analysts have placed a $380.25 one year price target on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). This is the consensus average based on 8 firms who have recently issued reports on the equity.
The average recommendation is the arithmetical average of the individual analyst ratings contributed by sell-side research to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 represents a Strong Buy and 5 represents a Strong Sell,Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is ranked 1.33 based on 8 broker recommendations. Of the 8 analyst estimates, the most bullish sees the stock reaching $500 within the next 12 months while the most bearish analyst sees the stock at $265 within the year.
Taking a look at the long term growth prospects of the stock, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A. The high end estimate for this time frame is $N/A with the low being $N/A.
According to analysts, Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is expected to report earnings per share for the current fiscal quarter of $-1.74. This is the consensus mean estimate based on the individual covering sell-side firm’s reported numbers. The company last reported earnings for the period ending on 2014-12-31 of $-1.63.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company’s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.